State of the Science Summit on Hematologic Malignancies | Conference

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas

July 3rd 2019

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

Cowan Highlights Practice-Changing Combo Regimens in Multiple Myeloma

July 3rd 2019

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

Expert Hopeful to Add Novel Agents to MPN Armamentarium

July 3rd 2019

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

Expert Sorts Through Treatment Strategies in Follicular Lymphoma

July 2nd 2019

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Influx of Targeted Therapies Prompts Several Questions in AML Paradigm

July 2nd 2019

Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.

Expert Highlights CAR-T and Other Treatment Advances Across Hematologic Malignancies

July 2nd 2019

Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

June 28th 2019

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

MRD Could Take Center Stage in Pediatric and Adult ALL Paradigms

June 27th 2019

Jerald P. Radich, MD, the methods that are used to measure minimal residual disease and the work being done to standardize its use in acute lymphoblastic leukemia.

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

June 4th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AML

May 31st 2019

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

Dr. Shah on Differences Between Anti-CD19 CAR T-Cell Therapies

May 30th 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Dr. Chhabra on Impactful Advances in Relapsed/Refractory Multiple Myeloma

May 15th 2019

Saurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.

Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

May 13th 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Targeted Therapies Transform Outlook of FLT3- and IDH-Mutant AML

May 8th 2019

Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.

Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies

May 8th 2019

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Post-Ibrutinib Treatments Show Promise in CLL

May 8th 2019

Sameem Abedin, MD, discusses the recent encouraging data in chronic lymphocytic leukemia with venetoclax, duvelisib, and acalabrutinib.

Dr. Hari Discusses the Role of MRD in Myeloma

May 8th 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.

Frontline Advances Propel Progress in Multiple Myeloma

May 7th 2019

Parameswaran Hari, MD, MRCP, discusses the rapidly evolving paradigm of myeloma with a focus on the latest updates in the frontline setting.

Dr. Fenske on the Future of Daratumumab in MCL

May 7th 2019

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

Emerging Agents Spur Optimism in Myeloma

May 7th 2019

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.